Efficacy and Safety of Twice-daily and Once-daily Olopatadine-Mometasone Combination Nasal Spray for Seasonal Allergic Rhinitis.

Efficacy and Safety of Twice-daily and Once-daily Olopatadine-Mometasone Combination Nasal Spray for Seasonal Allergic Rhinitis. Ann Allergy Asthma Immunol. 2019 Nov 14;: Authors: Andrews CP, Mohar D, Salhi Y, Tantry SK Abstract BACKGROUND: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). OBJECTIVE: To evaluate efficacy and safety of GSP301 in patients with seasonal AR (SAR). METHODS: In this phase 2, double-blind, parallel-group study, patients (≥12 years of age) with SAR were equally randomized to twice-daily GSP301 (olopatadine 665μg and mometasone 25μg), once-daily GSP301 (olopatadine 665μg and mometasone 50μg), twice-daily or once-daily olopatadine monotherapy (665μg), mometasone monotherapy (twice-daily 25μg or once-daily 50μg), or placebo for 14 days. The primary endpoint-mean change from baseline in morning and evening reflective Total Nasal Symptom Score (rTNSS)-was analyzed using ANCOVA (P
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Ann Allergy Asthma Immunol Source Type: research

Related Links:

Objective: to evaluate the clinical efficacy and safety of long-term anti-IgE therapy patients with severe uncontrolled asthma.Materials and Methods: in Chelyabinsk city from November 2016 35 patients regularly receive omalizumab therapy - 9 men (26%) and 26 women (74%), the average age 44.5±14.1 years, the duration of asthma - 25.2±11.5 years. All patients had allergic pathology: allergic rhinitis - 100%, pollinosis - 79.4%, food allergy - 44.1%, atopic dermatitis - 26.5%. The level of total IgE in the blood is from 72 to 787 IU/ml, high sesitization to household (88.6%), epidermal (62.9%), pollen (74.3%) al...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Airway pharmacology and treatment Source Type: research
A few studies have suggested an interaction between air pollution and pollen exposure on allergy symptoms but more research is needed. As part of the POLLAR (Impact of Air Pollution in Asthma and Rhinitis) project, we investigated the associations between major air pollutants (ozone and PM2.5) and allergic rhinitis control, during grass and birch pollen seasons, using the Allergy Diary app (a validated mHealth tool for allergic rhinitis management). The daily impact of allergic symptoms was recorded, using visual analogue scale (VAS), by 3,328 geolocated app users in 2017 and 2018 in Northern Europe, representing 36,523 VA...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Occupational and environmental health Source Type: research
GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid).
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Subcutaneous immunotherapy is effective for treatment of allergic rhinitis, allergic asthma, and chronic rhinosinusitis. Rapid desensitization (rush immunotherapy) offers advantages of faster efficacy, improved compliance, and  cost effectiveness. While premedication with corticosteroids and antihistamines substantially reduce the incidence of systemic reactions, safety is the primary concern for allergists.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: NAEB, CVA, and UACS are common causes of chronic cough in patients with AR. FeNO can first be used to discriminate patients with CVA/NAEB, then FEF25-75 (or combined with FeNO) can further discriminate patients with CVA from those with CVA/NAEB. PMID: 31552718 [PubMed]
Source: Allergy, Asthma and Immunology Research - Category: Allergy & Immunology Tags: Allergy Asthma Immunol Res Source Type: research
Publication date: July–August 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 6Author(s): Sarah Diver, Richard J. Russell, Christopher E. BrightlingEosinophilic airway inflammation is observed in 30% to 50% of chronic cough sufferers. It is a common feature of asthma and upper airway cough syndrome, and it is required in the diagnosis of nonasthmatic eosinophilic bronchitis. Our understanding of the mechanisms underlying allergic and nonallergic eosinophilic inflammation have evolved tremendously in the last 2 decades, but the cause of this inflammation in any individual is of...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
ConclusionsThis study revealed a high frequency of relevant comorbidities and that a substantial proportion of patients have late-onset asthma; all these features define specific different disease phenotypes. Severe asthma complexity and comorbidities require multidisciplinary approaches, led by specifically trained pulmonologists and allergists.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
This study evaluated the effects of dried ginger and LGWWJX decoction on cold asthma at the metabolomics level. It provides a reference for the research on the compatibility of Chinese Medicine. Introduction Ginger is a Chinese medicine (CM) used as a food and as a medicine, and is often used to treat cold syndrome through the property of warming. Dried ginger (Zingiberis Rhizoma, GanJiang, GJ) is processed from fresh ginger and is also commonly used in CM. It is used to treat cold asthma by “warming the stomach to dispel cold, warming the lung to resolve fluid,” and it has significant anti-inflammatory...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
ConclusionMP ‐AzeFlu provided effective, rapid, and sustained symptom control in a real‐life setting among patients from Denmark. These results align with EU and ARIA objectives and support the effectiveness of MP‐AzeFlu for the treatment of AR in real life.
Source: International Forum of Allergy and Rhinology - Category: Allergy & Immunology Authors: Tags: ORIGINAL ARTICLE Source Type: research
GSP301 nasal spray is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid).
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Original Article Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Corticosteroid Therapy | Hay Fever | Mometasone | Nasonex | Statistics | Study